Letters to the Editor Open access

Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer

Authors

Published
3 May 2022
Section
Letters to the Editor
DOI
10.4081/reumatismo.2022.1482

Abstract

Not available

References

  1. Maranini B, Ciancio G, Cultrera R, Govoni M. Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo. 2021; 73: 1445. DOI: https://doi.org/10.4081/reumatismo.2021.1445
  2. Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015; 1: 15016. DOI: https://doi.org/10.1038/nrdp.2015.16
  3. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020; 7: ofaa005. DOI: https://doi.org/10.1093/ofid/ofaa005
  4. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014; 81: 215-21. DOI: https://doi.org/10.1016/j.jbspin.2013.07.009
  5. Ting SW, Ting SY, Lin YS, et al. Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study. Sci Rep. 2021; 11: 11824. DOI: https://doi.org/10.1038/s41598-021-91356-3
  6. Chiu YM, Tang CH, Hung ST, et al. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017; 46: 236-40. DOI: https://doi.org/10.1080/03009742.2016.1202318
  7. Khazan M, Nasiri S, Riahi SM, et al. Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster. J Med Virol. 2020; 92: 1253-9. DOI: https://doi.org/10.1002/jmv.25484
  8. Bauer ME, Fuente Mde L. The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev. 2016; 158: 27-37. DOI: https://doi.org/10.1016/j.mad.2016.01.001
  9. Tozzi AE, Asturias EJ, Balakrishnan MR, et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013; 31: 5041-6. DOI: https://doi.org/10.1016/j.vaccine.2013.08.087
  10. Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel). 2021; 9: 6. DOI: https://doi.org/10.3390/vaccines9060572
  11. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79: 39-52. DOI: https://doi.org/10.1136/annrheumdis-2019-215882
  12. Bijlsma JW. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis. 2021. [Epub ahead of print]. DOI: https://doi.org/10.1136/annrheumdis-2020-219773
  13. Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021; 60: 5149-57. DOI: https://doi.org/10.1093/rheumatology/keab139
  14. FDA. Shingrix 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix
  15. Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018; 8: e020528. DOI: https://doi.org/10.1136/bmjopen-2017-020528
  16. Curran D, Hunjan M, El Ghachi A, El-Hahi Y, Bianco V, Ferreira G. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. 2019; 9: e023502. DOI: https://doi.org/10.1136/bmjopen-2018-023502
  17. Munoz-Quiles C, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014. BMC Infect Dis. 2020; 20: 905. DOI: https://doi.org/10.1186/s12879-020-05648-6
  18. Matthews I, Duong M, Parsons VL, et al. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK. PLoS One. 2020; 15: e0229224. DOI: https://doi.org/10.1371/journal.pone.0229224
  19. Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol. 2020; 20: 451-2. DOI: https://doi.org/10.1038/s41577-020-0372-8
  20. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021. [Epub ahead of print]. DOI: https://doi.org/10.1136/annrheumdis-2021-221490

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2022 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.